Here is a selection of this week's latest news from around the world
 |
 |
|
Launch of largest ever UK lung cancer screening studyThe largest ever lung cancer screening project undertaken in the UK has launched in London, aiming to detect lung cancer early among at-risk citizens. To read more follow this PharmaTimes link |
Roche wins key cancer drug approval, but taking on Merck remains a challengeLast week, Tecentriq secured an OK from the Food and Drug Administration for previously untreated patients with metastatic non-squamous non-small cell lung cancer (NSCLC), making it the second checkpoint inhibitor behind Merck's rival Keytruda cleared for use in the first-line lung cancer setting. To read more follow this BioPharmaDive link |
|
 |
 |
|
Axovant drops small molecule development after dementia drug failureAxovant Sciences will stop developing its small molecule drug portfolio, the company said Monday, following the failure of its experimental drug candidate nelotanserin in a Phase 2 trial of patients with Lewy body dementia who experience REM sleep behavior disorder To read more follow this BioPharmaDive link |
|
Scientists develop revolutionary tech to improve prostate cancer detectionA ‘revolutionary’ new medical software able to pinpoint the area from which surgeons should take a biopsy to detect prostate cancer has been developed by NIHR supported researchers To read more follow this PharmaTimes link |
 |
 |
|
CEPI, Imperial College partner for emerging diseases vaccinesThe Coalition for Epidemic Preparedness Innovations (CEPI) and Imperial College London have announced a partnership to develop a self-amplifying RNA vaccine platform (saRNA), enabling tailored vaccine production against multiple viral pathogens To read more follow this PharmaTimes Link |
Drug Launch of the Year: Amgen and Novartis' AimovigAmgen and Novartis, in winning approval for their new migraine drug Aimovig this May, laid first claim to a market Wall Street has pegged as a multi-billion dollar opportunity To read more follow this BioPharmaDive link |